Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The expanded collaboration now allows Reddit to use Google’s Vertex AI, which enables users to build, deploy, and scale machine learning models and AI applications, the author notes. Easily ...

Vertex Pharmaceuticals has analysts doing financial backflips as they boost its price targets, with Royal Bank of Canada ...